**Supplementary Table 1. Clinical and laboratory parameters in chronic liver disease patients**

|  |  |  |  |
| --- | --- | --- | --- |
| Variables | | No. | % |
| Platelets categories | **Normal (>=150)** | 12 | 40.0% |
| **Thrombocytopenia (<150)** | 18 | 60.0% |
| AFP categories | **Normal (0-19)** | 30 | 100.0% |
| **Mildly elevated (20-100)** | 0 | 0.0% |
| **Moderately elevated (101-200)** | 0 | 0.0% |
| **Severely elevated (201-1000)** | 0 | 0.0% |
| **Extremely elevated (>1000)** | 0 | 0.0% |
| ALBI categories | **Grade I (<=-2.60)** | 0 | 0.0% |
| **Grade 2 (>-2.60-<=-1.39)** | 21 | 70.0% |
| **Grade 3 (>-1.39)** | 9 | 30.0% |
| CRP categories | **Normal (<=6)** | 24 | 80.0% |
| **Elevated (>6)** | 6 | 20.0% |
| NLR categories | **Normal (1-5)** | 12 | 40.0% |
| **Mild (6-8)** | 3 | 10.0% |
| **Moderate (9-18)** | 15 | 50.0% |
| **Severe (>18)** | 0 | 0.0% |
| PLR categories | **Low levels (<106)** | 6 | 20.0% |
| **Normal levels (106-300)** | 15 | 50.0% |
| **High levels (>300)** | 9 | 30.0% |
| AST/ALT ratio categories | **Low (<=1)** | 6 | 20.0% |
| **High (>1)** | 24 | 80.0% |
| FIB 4 categories | **Stage 0-1 (<1.45)** | 6 | 20.0% |
| **Stage 2-3 (1.45-3.25)** | 3 | 10.0% |
| **Stage 4-6 (stage 4-6)** | 21 | 70.0% |
| APRI categories | **No significant fibrosis (<0.07)** | 9 | 30.0% |
| **Significant fibrosis (0.7-1)** | 6 | 20.0% |
| **Severe fibrosis/Cirrhosis (>1)** | 15 | 50.0% |
| NFS categories | **F0-F2 (<-1.455)** | 6 | 20.0% |
| **Indeter. Score (-1.455-0.675)** | 3 | 10.0% |
| **F3-F4 (>0.675)** | 21 | 70.0% |
| CTP score | **A** | 9 | 30.0% |
| **Early B** | 0 | 0.0% |
| **Late B** | 12 | 40.0% |
| **C** | 9 | 30.0% |
| MELD categories | **Low risk (<10)** | 0 | 0.0% |
| **Moderate risk (10-19)** | 27 | 90.0% |
| **High risk (20-30)** | 3 | 10.0% |
| **Very high (>30)** | 0 | 0.0% |

AFP, alpha-fetoprotein; ALBI, Albumin-Bilirubin; ALT, alanine aminotransaminase; APRI, Aspartate Aminotransferase to Platelet Ratio Index; AST,  aspartate aminotransferase; CRP, C. reactive protein; CTP, Child-Turcotte-Pugh; FIB-4, Fibrosis-4; MELD, Model for End-Stage Liver Disease; NFS, NAFLD Fibrosis Score; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.